ArticleBalkan medical journal2021
Inhibition of YBX1 by miR-216a Suppresses Proliferation and Invasion of Diffuse Large B-Cell Lymphoma.
Article in Balkan medical journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 7 citations in OpenAlex.
- YBX1: an RNA/DNA-binding protein that affects disease progression.Frontiers in oncology · 2025Review
- Advances in epigenetic therapies for B-cell non-hodgkin lymphoma.Annals of hematology · 2024Review
- Readers of RNA Modification in Cancer and Their Anticancer Inhibitors.Biomolecules · 2024Review
- Y-Box Binding Protein 1: Unraveling the Multifaceted Role in Cancer Development and Therapeutic Potential.International journal of molecular sciences · 2024Review
- Ferroptosis-related prognostic model of mantle cell lymphoma.Open medicine (Warsaw, Poland) · 2024Article
- Molecular mechanisms of microRNA-216a during tumor progression.Cancer cell international · 2023Review
- Crocin ameliorates MicroRNAs-associated ER stress in type 2 diabetes induced by methylglyoxal.Iranian journal of basic medical sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMicroRNAs (miRNAs) could be implicated in tumorigenesis of diffuse large B-cell lymphoma (DLBCL).
aimsTo determine the role of MiR-216a in DLBCL. STUDY
designCell culture study.
methodsExpression of miR-216a in DLBCL cells was examined by qRT-PCR. Cell counting kit-8, bromodeoxyuridine staining and transwell assays were performed to evaluate role of miR-216a on DLBCL cell growth. Target gene of miR-216a was verified by luciferase reporter assay.
resultsMiR-216a was dramatically reduced in DLBCL cells compared to the normal B-cell line (P < .01). MiR-216a reduced the viability and retarded DLBCL cell proliferation. The invasion of DLBCL was suppressed by miR-216a. Y box binding protein 1 (YBX1) was validated as a target of miR-216a. Its expression was reduced by miR-216a mimic and enhanced by miR-216a inhibitor in DB and SU-DHL-10 cells. Knockdown of YBX1 reduced cell viability, proliferation, and invasion of DB and SU-DHL-10 cells.
conclusionMiR-216a exerted tumor-suppressive effects on DLBCL cells through inhibition of YBX1, providing a new strategy for DLBCL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.